Breaking News

Japan July Industrial Output Rises 0.2% Against Estimated 1% Gain
Tweet TWEET

Blueprint Medicines Welcomes Daniel S. Lynch to its Board of Directors as Executive Chairman; Announces Permanent Appointment of

  Blueprint Medicines Welcomes Daniel S. Lynch to its Board of Directors as
  Executive Chairman; Announces Permanent Appointment of Chris Varma, Ph.D.,
  as Chief Executive Officer

Business Wire

CAMBRIDGE, Mass. -- November 13, 2012

Blueprint Medicines, a company harnessing the understanding of the molecular
blueprint of cancer to develop personalized, highly-selective cancer
therapies, today announced the addition of Daniel S. Lynch as executive
chairman of its board of directors. In addition, Blueprint Medicines announced
that Chris Varma, Ph.D., founding president and chief executive officer of
Blueprint Medicines and entrepreneur-in-residence (EIR) at Third Rock
Ventures, has been appointed as permanent president and chief executive
officer.

“I am delighted to welcome Dan to our board as executive chairman and excited
to continue to lead the exceptional team we have assembled at Blueprint
Medicines,” said Dr. Varma. “Blueprint Medicines is well positioned to
leverage our proprietary genomics platform and extensive chemical library to
transform the current treatment paradigm for cancer and develop truly
personalized cancer medicines for patients of high unmet need.”

Mr. Lynch brings more than 25 years of experience serving in management and
board positions in the biotechnology and pharmaceutical industries. Mr. Lynch
spent nearly five years at ImClone Systems, serving as chief executive officer
and chief financial officer. As CEO, he led ImClone through a significant
turnaround, including securing FDA approval of ERBITUX® (cetuximab), an
important new cancer treatment. As CFO, Mr. Lynch led negotiations to form the
major partnership between ImClone and Bristol-Myers Squibb. Earlier in his
career, he served in various financial positions at Bristol-Myers Squibb over
a 15-year tenure. He served on the board of directors and the audit committee
of U.S. Oncology, Inc. for five years until December 2010 when it was acquired
by McKesson. More recently, Mr. Lynch was executive chairman of the board for
Avila Therapeutics and Stromedix, which were successfully acquired by Celgene
and Biogen Idec Inc., respectively. In addition to Blueprint Medicines, Mr.
Lynch is currently a member of the board of directors for bluebird bio, Edimer
Pharmaceuticals, Ember Therapeutics and BIND Biosciences. Mr. Lynch received
his B.A. in mathematics from Wesleyan University and his MBA from the Darden
Graduate School of Business Administration at the University of Virginia.

“I believe there is great promise in the company's ability to identify and
validate potential drivers of cancer and leverage these insights to develop
highly selective therapies,” said Mr. Lynch. “It is an exciting time to join
the company’s board and be part of its growth and development under Chris’
leadership.”

Dr. Varma co-founded Blueprint Medicines at Third Rock Ventures, a Boston
based life sciences venture capital firm, where he joined the firm to develop
and build new companies as an entrepreneur-in-residence. While at Third Rock
Ventures, Dr. Varma also helped to create Warp Drive Bio. Prior to Third Rock
Ventures, Dr. Varma was a partner at Flagship Ventures focusing on life
science investments. During his last year at Flagship, he also served as the
president, chief executive officer and director of Selventa (formerly known as
Genstruct, Inc.), a Flagship portfolio company, where he led a rapid
turnaround that achieved profitability in less than a year. Before joining
Flagship, he oversaw efforts spanning clinical development, business
development and sales and marketing at Novartis AG. Prior to Novartis, he was
at Millennium Pharmaceuticals, and before that worked for the U.S. Food and
Drug Administration. Dr. Varma holds a Ph.D. in biomedical engineering from
the Harvard-MIT Division of Health Sciences & Technology, a M.S. in management
from Stanford University, and both a M.S. and B.S. in computer science from
Stanford University.

Mark Levin, partner, Third Rock Ventures and board member, Blueprint Medicines
added, "While we are sad to lose Chris at Third Rock, the appointment of Chris
to CEO of Blueprint Medicines is an excellent example of our approach to
building great companies with the best talent. We look forward to working with
Chris, Dan and the rest of the team to realize the full potential of the
Blueprint Medicines approach to personalized cancer medicine.”

About Blueprint Medicines

Blueprint Medicines is driving the development of personalized, highly
selective cancer therapies that harness the growing understanding of the
molecular blueprint of cancer. Using its powerful Insights-to-Validation™
Platform and proprietary chemical library, Blueprint Medicines is working to
develop new therapeutic compounds and combination therapies that target the
molecular aberrations that cause cancer and the emerging resistance mechanisms
that make it increasingly difficult to treat. Blueprint Medicines was founded
in 2011 by a proven team of scientists, including Nicholas Lydon, Ph.D., and
Brian Druker, M.D., entrepreneurs with world-renowned expertise in the
development of targeted cancer therapies, cancer genomics, and rational drug
development, and Third Rock Ventures. Fidelity Biosciences joined as an
investor in 2012. Blueprint Medicines is poised to realize the promise of the
cancer data “revolution”: truly personalized therapies that improve outcomes
and shift cancer to a manageable condition. For more information on Blueprint
Medicines, please visit the company’s website at www.blueprintmedicines.com.

Contact:

Pure Communications
Dan Budwick, 973-271-6085
dan@purecommunicationsinc.com
 
Press spacebar to pause and continue. Press esc to stop.